ArticleBMC geriatrics2025
Fibrinogen-to-albumin ratio and long-term mortality in oldest-old patients undergoing percutaneous coronary intervention.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of an interpretable machine learning model for predicting atrial fibrillation risk in middle-aged and older patients with coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- Risk and all-cause mortality of high low-density lipoprotein cholesterol-albumin ratio level in stable coronary artery disease patients following percutaneous coronary intervention.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe fibrinogen-to-albumin ratio (FAR), a novel inflammatory marker, has demonstrated prognostic utility in cardiovascular diseases. However, its role in risk stratification among oldest-old patients (≥ 80 years) undergoing percutaneous coronary intervention (PCI) remains poorly established.
methodsThis single-center retrospective cohort study enrolled 641 consecutive patients aged ≥ 80 years with coronary artery disease who underwent PCI between 2015 and 2021. Based on the median FAR value (0.079), patients were divided into higher FAR and lower FAR groups. The endpoints were cardiovascular and all-cause mortality. Multivariable Cox models and restricted cubic splines assessed the associations between FAR and endpoints.
resultsDuring a median follow-up of 61 months, 237 deaths (37%) were recorded, of which, 124 (19.3%) were due to cardiovascular disease. The 1-year mortality was 9.3% and 5-year mortality was 27.4%. Kaplan-Meier analysis demonstrated higher FAR levels were significantly associated with increased risk of both cardiovascular and all-cause mortality (log-rank p < 0.001). According to the restricted cubic spline, the association between FAR and mortality was J-shaped. Higher FAR (> 0.079) independently predicted cardiovascular mortality (adjusted HR = 1.49, 95% CI:1.01-2.19, p = 0.045). When tested as a continuous variable, higher FAR levels were associated with a higher risk of cardiovascular (HR = 1.23, 95% CI: 1.04-1.47, p = 0.018) and all-cause mortality (HR = 1.12, 95%CI: 0.98-1.27, p = 0.090) in fully adjusted models. Subgroup analysis revealed that the association between higher FAR levels and increased cardiovascular mortality was significantly stronger in patients with triple-vessel disease (interaction p = 0.039). The associations between FAR and cardiovascular mortality remained robust in the Fine and Gray competing models (HR = 1.31, 95%CI: 1.13-1.52, p = 0.003).
conclusionHigher FAR levels are associated with increased risks of cardiovascular and all-cause mortality in oldest-old patients undergoing PCI. These findings support the potential of FAR for risk stratification in geriatric cardiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.